Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis

References

• International Diabetes Federation. IDF diabetes atlas. Brussels, Belgium; 2019. Available from: https://www.diabetesatlas.org. Accessed September 10, 2021.
   Google Scholar
• Centers for Disease Control and Prevention. National diabetes statistics report. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2020. Available from. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed September 10, 2021.
   Google Scholar
• Zaccardi F, Dhalwani NN, Webb DR, Davies MJ, Khunti K. Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates. Diabetologia. 2018;61(7):1592–1602. doi:10.1007/s00125-018-4626-y
   Web of Science ®Google Scholar
• Mahoney GK, Henk HJ, McCoy RG. Severe hypoglycemia attributable to intensive glucose-lowering therapy among US adults with diabetes: population-based modeling study, 2011–2014. Mayo Clin Proc. 2019;94(9):1731–1742. doi:10.1016/j.mayocp.2019.02.028
   PubMed Web of Science ®Google Scholar
• Halter JB, Musi N, McFarland Horne F, et al. diabetes and cardiovascular disease in older adults: current status and future directions. Diabetes. 2014;63(8):2578–2589. doi:10.2337/db14-0020
   PubMed Web of Science ®Google Scholar
• Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–1418. doi:10.1056/NEJMoa1003795
   PubMed Web of Science ®Google Scholar
• Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab. 2003;284(1):E7–E12. doi:10.1152/ajpendo.00366.2002
   PubMed Web of Science ®Google Scholar
• Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care. 2015;38(4):588–595. doi:10.2337/dc14-0599
   Web of Science ®Google Scholar
• Kumar JG, Abhilash KP, Saya RP, Tadipaneni N, Bose JM. A retrospective study on epidemiology of hypoglycemia in Emergency Department. Indian J Endocrinol Metab. 2017;21(1):119–124. doi:10.4103/2230-8210.195993
   Google Scholar
• Hodge M, McArthur E, Garg AX, Tangri N, Clemens KK. Hypoglycemia incidence in older adults by estimated GFR. Am J Kidney Dis. 2017;70(1):59–68. doi:10.1053/j.ajkd.2016.11.019
   Web of Science ®Google Scholar
• Kim HM, Seong JM, Kim J. Risk of hospitalization for hypoglycemia among older Korean people with diabetes mellitus: interactions between treatment modalities and comorbidities. Medicine. 2016;95(42):e5016. doi:10.1097/MD.0000000000005016
   Web of Science ®Google Scholar
• Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Céron D. Possible interaction between gliclazide, fluconazole, and sulfamethoxazole resulting in severe hypoglycaemia. Br J Clin Pharmacol. 2001;52(4):456–457. doi:10.1046/j.0306-5251.2001.01456.x-i2
   Web of Science ®Google Scholar
• American Diabetes Association. 11. older adults: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl1):S119–S125. doi10.2337/dc18-S011
   Web of Science ®Google Scholar
• Renom-Guiteras A, Meyer G, Thurmann PA, The EU. (7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861–875. doi:10.1007/s00228-015-1860-9
   PubMed Web of Science ®Google Scholar
• By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American geriatrics society 2019 updated AGS beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–694. doi10.1111/jgs.15767
   PubMed Web of Science ®Google Scholar
• [product monograph]. Diamicron® MR (gliclazide modified release). Laval, Quebec, Canada: Servier Canada Inc; last revised Sep 2019. Available from https://pdf.hres.ca/dpd_pm/00053765.PDF. Accessed September 10, 2021.
   Google Scholar
• Amaryl® (glimepiride) prescribing information. Bridgewater, NJ: Sanofi-Aventis; 2018. Available from https://products.sanofi.us/Amaryl/Amaryl.pdf. Accessed September 10, 2021.
   Google Scholar
• Clemens KK, McArthur E, Dixon SN, Fleet JL, Hramiak I, Garg AX. The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide. Can J Diabetes. 2015;39(4):308–316. doi:10.1016/j.jcjd.2015.01.001
   Web of Science ®Google Scholar
• Hamad medical corporation, international accreditations. Available from https://www.hamad.qa/EN/About-Us/Our-Accreditations/Pages/default.aspx. Accessed September 10, 2021.
   Google Scholar
• Seaquist ER, Anderson J, Childs B, et al. hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384–1395. doi:10.2337/dc12-2480
   PubMed Web of Science ®Google Scholar
• Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157(15):1681–1686. doi:10.1001/archinte.1997.00440360095010
   PubMed Web of Science ®Google Scholar
• Glyburide, gliclazide or glimepiride for elderly patients with type 2 diabetes: a review of the clinical effectiveness and safety – an update [internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015. Available from: https://www.ncbi.nlm.nih.gov/books/NBK315873. Accessed May 10, 2022.
   Google Scholar
• Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract. 2015;110(1):75–81. doi:10.1016/j.diabres.2015.07.002
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535–542. doi:10.1111/j.1365-2362.2004.01381.x
   PubMed Web of Science ®Google Scholar
• Hemmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;(4):CD009008. doi:10.1002/14651858.CD009008.pub2
   Web of Science ®Google Scholar
• Hassan MH, Abd-Allah GM. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. Pak J Pharm Sci. 2015;28(5):1723–1730.
   Web of Science ®Google Scholar
• Cho EH, Han K, Kim B, Lee DH. Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus. Medicine. 2020;99(29):e21236. doi:10.1097/MD.0000000000021236
   Web of Science ®Google Scholar